ArticleAdvanced functional materials2020
Biodegradable nanofibrous temperature-responsive gelling microspheres for heart regeneration.
Article in Advanced functional materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 72 citations in OpenAlex.
- Extracellular matrix-mimic nanofibrous microspheres: fabrication and application in stem cell delivery for tissue repair and regeneration.Materials today. Bio · 2026Review
- Research advances in intelligent microenvironment-responsive hydrogels for myocardial infarction therapy.APL bioengineering · 2026Review
- Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.International journal of nanomedicine · 2026Review
- Smart bioactive hydrogels for myocardial infarction repair: a multifunctional approach integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing.Annals of medicine and surgery (2012) · 2026Review
- 3D-Printed Microfluidic Platform for Creating Porous Nanofibrous Microspheres to Regulate Cell Response and Enhance Tissue Regeneration.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Advanced Nanomaterial Platforms for Targeted Therapy of Myocardial Ischemia-Reperfusion Injury.Research (Washington, D.C.) · 2025Review
- Monascus pigment-protected bone marrow-derived stem cells for heart failure treatment.Bioactive materials · 2024Article
- Recent advances in shape memory scaffolds and regenerative outcomes.Biomedical engineering letters · 2024Review
- Innovative wound management: creating dynamic Alg-Mg/SF hydrogels for controlled MgRSC advances · 2024Article
- Cardiac tissue engineering: an emerging approach to the treatment of heart failure.Frontiers in bioengineering and biotechnology · 2024Review
- Transplantation of Stem Cell Spheroid-Laden 3-Dimensional Patches with Bioadhesives for the Treatment of Myocardial Infarction.Biomaterials research · 2024Article
- Functional microspheres for tissue regeneration.Bioactive materials · 2023Review
- The Role of Hydrogel in Cardiac Repair and Regeneration for Myocardial Infarction: Recent Advances and Future Perspectives.Bioengineering (Basel, Switzerland) · 2023Review
- Emulsion-induced polymersomes taming tetrodotoxin for prolonged duration local anesthesia.Advanced therapeutics · 2023Article
- A physicochemical double-cross-linked gelatin hydrogel with enhanced antibacterial and anti-inflammatory capabilities for improving wound healing.Journal of nanobiotechnology · 2022Article
- Fabrication of Tβ4-Exosome-releasing artificial stem cells for myocardial infarction therapy by improving coronary collateralization.Bioactive materials · 2022Article
- Poly(Gels (Basel, Switzerland) · 2022Review
- Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment.Pharmaceutics · 2022Review
- Injectable Composite Systems Based on Microparticles in Hydrogels for Bioactive Cargo Controlled Delivery.Gels (Basel, Switzerland) · 2021Review
- Applications of capillary action in drug delivery.iScience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Myocardial infarction (heart attack) is the number one killer of heart patients. Existing treatments for heart attack do not address the underlying problem of cardiomyocyte (CM) loss and cannot regenerate the myocardium. Introducing exogenous cardiac cells is required for heart regeneration due to the lack of resident progenitor cells and very limited proliferative potential of adult CMs. Poor retention of transplanted cells is the critical bottleneck of heart regeneration. Here, we report the invention of a poly(l-lactic acid)-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.